European experience with the Afirma Gene Expression Classifier for indeterminate thyroid nodules: A clinical utility study in the Netherlands
Head & Neck · 2023-09 · 45 (9) · 2227-2236
DOI: 10.1002/hed.27472 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Head & Neck, online erschienen am 25.07.2023. Verfasst von Ivona Lončar und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Thyroid Nodule, Thyroid Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Veracyte.
Abstract (Originalsprache)
Background
The Gene Expression Classifier (GEC) and Genomic Sequencing Classifier (GSC) were developed to improve risk stratification of indeterminate nodules. Our aim was to assess the clinical utility in a European population with restrictive diagnostic workup.
Methods
Clinical utility of the GEC was assessed in a prospective multicenter cohort of 68 indeterminate nodules. Diagnostic surgical rates for Bethesda III and IV nodules were compared to a historical cohort of 171 indeterminate nodules. Samples were post hoc tested with the GSC.
Results
The GEC classified 26% as benign. Surgical rates between the prospective and historical cohort did not differ (72.1% vs. 76.6%). The GSC classified 59% as benign, but misclassified six malignant lesions as benign.
Conclusion
Implementation of GEC in management of indeterminate nodules in a European country with restrictive diagnostic workup is currently not supported, especially in oncocytic nodules. Prospective studies with the GSC in European countries are needed to determine the clinical utility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
- Department of Internal Medicine, Erasmus MC Academic Center for Thyroid Diseases, Rotterdam, the Netherlands.
- Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands.
- Department of Pathology, Erasmus MC, Rotterdam, the Netherlands.
- Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands.
- Department of Pathology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
ORCID-Profile: Ivona Lončar
Förderung
- Veracyte
Zitieren
APA
Lončar, I., van Velsen, E. F. S., Massolt, E. T., van Kemenade, F. J., van Engen-van Grunsven, A. C. H., van Hemel, B. M., van Nederveen, F. H., Netea-Maier, R., Links, T. P., Peeters, R. P., & van Ginhoven, T. M. (2023). European experience with the Afirma Gene Expression Classifier for indeterminate thyroid nodules: A clinical utility study in the Netherlands. Head & Neck, 45(9), 2227-2236. https://doi.org/10.1002/hed.27472
Vancouver
Lončar I, van Velsen EFS, Massolt ET, van Kemenade FJ, van Engen-van Grunsven ACH, van Hemel BM, et al. European experience with the Afirma Gene Expression Classifier for indeterminate thyroid nodules: A clinical utility study in the Netherlands. Head & Neck. 2023;45(9):2227-2236. doi:10.1002/hed.27472
BibTeX
@article{Lonar2023,
author = {Lončar, Ivona and van Velsen, Evert F S and Massolt, Elske T and van Kemenade, Folkert J and van Engen-van Grunsven, Adriana C H and van Hemel, Bettien M and van Nederveen, Francien H and Netea-Maier, Romana and Links, Thera P and Peeters, Robin P and van Ginhoven, Tessa M},
title = {European experience with the Afirma Gene Expression Classifier for indeterminate thyroid nodules: A clinical utility study in the Netherlands},
journal = {Head & Neck},
year = {2023},
volume = {45},
number = {9},
pages = {2227--2236},
doi = {10.1002/hed.27472}
}
EUVIMED